Summary

Complex pharmacovigilance legislation in an evolving regulatory landscape has left drug makers searching for current, efficient, and more meaningful solutions for their drug safety challenges, especially in the post-marketing arena. Companies are seeking expert advice and customized approaches to effectively collect, manage, and analyze real-world evidence for a competitive advantage. PRA’s Safety and Risk Management (SRM) and Late Phase Services (LPS) experts provide our clients with unique strategies from years of first-hand experience. PRA’s global SRM and LPS divisions have identified innovative solutions that satisfy key regulatory requirements to meet our clients’ risk management planning and execution needs.

Register to download

Risk Management Planning & Mandated Post-Authorization Studies